ninlaro
takeda pharma a/s - iksasomibtsitraat - mitu müeloomit - antineoplastilised ained - ninlaro kombinatsioonis lenalidomiidi ja deksametasooniga on näidustatud hulgimüeloomiga täiskasvanud patsientide raviks, kellel on vähemalt üks eelnevat ravi.
tobradex silmasalv
novartis baltics sia - deksametasoon+tobramütsiin - silmasalv - 1mg+3mg 1g 3.5g 1tk
otoxolan kõrvatilgad, suspensioon
krka, d.d., novo mesto - deksametasoon+marbofloksatsiin+klotrimasool - kõrvatilgad, suspensioon - 0,9mg+3mg+10mg 1ml 30ml 1tk; 0,9mg+3mg+10mg 1ml 20ml 1tk
aurizon kõrvatilgad, suspensioon
vetoquinol s.a. - deksametasoon+marbofloksatsiin+klotrimasool - kõrvatilgad, suspensioon - 0,9mg+3mg+10mg 1ml 20ml 1tk; 0,9mg+3mg+10mg 1ml 10ml 1tk
marbodex kõrvatilgad, suspensioon
norbrook laboratories (ireland) limited - deksametasoon+marbofloksatsiin+klotrimasool - kõrvatilgad, suspensioon - 0,9mg+3mg+10mg 1ml 30ml 1tk
emend
merck sharp & dohme b.v. - aprepitant - vomiting; postoperative nausea and vomiting; cancer - antiemeetikumid ja antinauseants, - emend 40 mg kõvakapslid on näidustatud pärast operatsioonijärgset iiveldust ja oksendamist (ponv) täiskasvanutel. emend on saadaval ka 80 mg ja 125 mg raske kapslid ennetamise iiveldus ja oksendamine, mis on seotud kõrgelt ja mõõdukalt emetogenic vähk, kemoteraapia täiskasvanud ja noorukid alates 12. eluaastast (vt eraldi ravimi omaduste kokkuvõte). emend on saadaval ka 165 mg raske kapslid ennetamise akuutsed ja hilisemad iiveldus ja oksendamine, mis on seotud väga emetogenic cisplatin põhineb vähi keemiaravi täiskasvanute ja vältimise iiveldus ja oksendamine on seotud mõõdukalt emetogenic vähi keemiaravi täiskasvanutel. emend on saadaval ka pulber suukaudse suspensiooni ennetamise iiveldus ja oksendamine, mis on seotud kõrgelt ja mõõdukalt emetogenic vähi keemiaravi lapsed, väikelastel ja imikutel vanuses 6 kuud kuni alla 12 aastat. emend 80 mg, 125 mg, 165 mg raske kapslid ja emend pulber suukaudse suspensiooni on esitatud osana kombineeritud ravi.
lenalidomide krka d.d. novo mesto (previously lenalidomide krka)
krka, d.d., novo mesto - lenalidomide hydrochloride monohydrate - multiple myeloma; lymphoma, follicular - immunosupressandid - multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) on näidustatud ravi täiskasvanud patsientidel, kellel on varem ravimata hulgimüeloom, kes ei ole abikõlblikud siirdamist. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) on näidustatud ravi täiskasvanud patsientidel, kellel on varem ravimata hulgimüeloom, kes ei ole abikõlblikud siirdamist. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).
lenalidomide krka d.d.
krka, d.d., novo mesto - lenalidomide hydrochloride hydrate - multiple myeloma; lymphoma, follicular; myelodysplastic syndromes - immunosupressandid - multiple myelomalenalidomide krka d. as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) on näidustatud ravi täiskasvanud patsientidel, kellel on varem ravimata hulgimüeloom, kes ei ole abikõlblikud siirdamist. lenalidomide krka d. in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka d. as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. follicular lymphomalenalidomide krka d. in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).
lenalidomide mylan
mylan ireland limited - lenalidomiid - mitu müeloomit - immunosupressandid - multiple myelomalenalidomide mylan as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide mylan as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. lenalidomide mylan in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide mylan in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1-3a).
lenalidomide krka (previously lenalidomide krka d.d. novo mesto)
krka, d.d., novo mesto - lenalidomide hydrochloride monohydrate - multiple myeloma; myelodysplastic syndromes; lymphoma, follicular; lymphoma, mantle-cell - immunosupressandid - multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) on näidustatud ravi täiskasvanud patsientidel, kellel on varem ravimata hulgimüeloom, kes ei ole abikõlblikud siirdamist. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 ja 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) on näidustatud ravi täiskasvanud patsientidel, kellel on varem ravimata hulgimüeloom, kes ei ole abikõlblikud siirdamist. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 ja 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).